The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian α-carbonic anhydrase isoforms
The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian α-carbonic anhydrase isoforms
复制标题
DOI：
10.1016/j.bmcl.2009.06.002
复制
发表时间：
2009-08-01
影响因子：
2.7
通讯作者：
Supuran, Claudiu T.
中科院分区：
文献类型：
--
作者：
Parkkila, Seppo;Innocenti, Alessio;Supuran, Claudiu T.
The protein tyrosine kinases (PTKs) are essential enzymes in cellular signaling processes that regulate cell growth, differentiation, migration and metabolism. Their inhibition was recently shown to constitute a new modality for treating cancers. Two clinically used PTK inhibitors (PTKIs), imatinib (Glivec (TM)/Gleevec (TM)) and nilotinib (Tasigna (TM)) were investigated for their effects on the zinc enzymes carbonic anhydrases (CAs, EC 4.2.1.1). The two PTKIs inhibited all 13 catalytically active mammalian isoforms CA I-XV with K(I)s in the range of 4.1 nM-20.2 mu M. CA I and CA II were the most potently inhibited isoforms (K(I)s of 4-32 nM), whereas CA VA and VB showed the lowest affinity for these drugs (K(I)s of 5.4-20.2 mu M). In cancer cells, these inhibitors may interact with CAs in addition to the targets for which they were designed, the PTKs. (C) 2009 Elsevier Ltd. All rights reserved.
